OTHER PUBLICATIONS & ABSTRACTS
Other Data
Evidence / Other
Prospective Cost-Effectiveness Analysis of Genomic Profiling in Breast Cancer
PUBLICATION: European Journal of Cancer. December 2013, Volume 49, Issue 18, Pages 3773–3779 AUTHORS: V.P. Retèl, M.A. Jooreb, C.A. Drukker, J.M. Bueno-de-Mesquita, M. Knauer, H. van Tinteren, S.C. Linn, W.H. van Harten SUMMARY: The total health care costs per patient were €26,786 for the 70-gene and €29,187 for AO. The Read More
Performance Characteristics of the MammaPrint® Breast Cancer Diagnostic Gene Signature
PUBLICATION: PERSONALIZED MEDICINE VOL. 10, NO. 8 | 17 Oct 2013 https://doi.org/10.2217/pme.13.88 AUTHORS: Leonie J.M. Delahaye, Diederik Wehkamp, Arno N. Floore, Rene Bernards, Laura J. van‘t Veer & Annuska M. Glas SUMMARY: Here we study these performance characteristics of the MammaPrint® (Agendia NV, Amsterdam, The Netherlands) 70-gene signature using the Read More
Association Between Genomic Recurrence Risk and Well-Being Among Breast Cancer Patients
PUBLICATION: BMC Cancer. 2013 Jun 18;13:295. doi: 10.1186/1471-2407-13-295. AUTHORS: Retèl V.P., Groothuis-Oudshoorn C.G., Aaronson N.K., Brewer N.T., Rutgers E.J., van Harten W.H. SUMMARY: Based on MINDACT: Women (n = 347, response rate 62%) reported high satisfaction with and a good understanding of the GEP information they received. Read more: Retèl Read More
Multigene Assays and Molecular Markers in Breast Cancer: Systematic Review of Health Economic Analyses
PUBLICATION: Breast Cancer Res Treat. 2013 Jun;139(3):621-37. doi: 10.1007/s10549-013-2559-1. Epub 2013 May 31. AUTHORS: Rouzier R., Pronzato P., Chéreau E., Carlson J., Hunt B., Valentine W.J. ABSTRACT: Breast cancer is the most common female cancer and is associated with a significant clinical and economic burden. Multigene assays and molecular Read More
MammaPrint Feasibility in a Large Tertiary Urban Medical Center: An Initial Experience
PUBLICATION: Scientifica (Cairo). 2012; 2012: 942507. Published online 2012 Dec 31. doi: 10.6064/2012/942507. AUTHORS: C. Francisco Espinel, Shaughn Keating, Hanina Hibshoosh, Bret Taback, Kathie-Ann Joseph, Mahmoud El-Tamer, and Sheldon Feldman SUMMARY: This study indicates that using MP/TP assay is feasible in a tertiary care center but there may be utility Read More
Lobular Histology and Response to Neoadjuvant Chemotherapy in Invasive Breast Cancer
PUBLICATION: Breast Cancer Res Treat. 2012 Nov;136(1):35-43. doi: 10.1007/s10549-012-2233-z. Epub 2012 Sep 8. AUTHORS: Lips E.H., Mukhtar R.A., Yau C., de Ronde J.J., Livasy C., Carey L.A., Loo C.E., Vrancken-Peeters M.J., Sonke G.S., Berry D.A., Van't Veer L.J., Esserman L.J., Wesseling J., Rodenhuis S., Shelley Hwang E.; I-SPY TRIAL Investigators. Read More
Comparison of Molecular Subtyping with BluePrint, MammaPrint, and TargetPrint to Local Clinical Subtyping in Breast Cancer Patients
PUBLICATION: Ann Surg Oncol. 2012 Oct;19(10):3257-63. doi: 10.1245/s10434-012-2561-6. Epub 2012 Aug 15. AUTHORS: Nguyen B., Cusumano P.G., Deck K., Kerlin D., Garcia A.A., Barone J..L, Rivera E., Yao K., de Snoo F.A., van den Akker J., Stork-Sloots L., Generali D. SUMMARY: The concordance between BluePrint and IHC/FISH subtyping was 94% Read More
